Back to Search
Start Over
Protalix BioTherapeutics surges 15% premarket; PLX-102 shows positive results
- Source :
- Plus Company Updates. May 11, 2020
- Publication Year :
- 2020
-
Abstract
- Protalix BioTherapeutics (NYSEMKT:PLX) announces positive results from a Phase 3 clinical trial, BRIDGE, evaluating enzyme replacement therapy pegunigalsidase alfa (PLX-102) in Fabry disease patients who previously received Takeda's (NYSE:TAK) Replagal [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.624024285